Quarterly ResultMay 7, 2026, 06:42 AM
Nuvalent Q1 Net Loss $(109.3)M; R&D Expenses $83.6M
AI Summary
Nuvalent, Inc. reported a significant increase in its net loss for the first quarter of 2026, reaching $(109.3) million, up from $(84.6) million in the prior year. This was primarily driven by higher research and development and general and administrative expenses as the clinical-stage biopharmaceutical company continues its development programs. Despite the losses, Nuvalent believes its existing cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months.
Key Highlights
- Nuvalent reported a net loss of $(109.3) million for the three months ended March 31, 2026, compared to $(84.6) million in Q1 2025.
- Net loss per share was $(1.39) for Q1 2026, up from $(1.18) in Q1 2025.
- Research and development expenses increased to $83.6 million in Q1 2026 from $74.4 million in Q1 2025.
- General and administrative expenses rose to $35.8 million in Q1 2026 from $20.4 million in Q1 2025.
- Cash and cash equivalents stood at $159.7 million as of March 31, 2026.
- Marketable securities totaled $1,127.7 million as of March 31, 2026.
- The company's accumulated deficit reached $(1.1) billion as of March 31, 2026.
- Net cash used in operating activities was $(92.4) million for the three months ended March 31, 2026.
Price Impact
More from NUVL